Company Research Report: SeqBiome



Company Overview



  • Name: SeqBiome

  • Mission: To measure, analyse, and interpret the microbiome using state-of-the-art molecular tools, providing customers with meaningful, actionable insights into microbiome.

  • Founded: 2020

  • Founders: No information is available

  • Key People:

  • Chief Executive Officer: Prof Marcus Claesson

  • Chief Technical Officer: Prof Paul Cotter

  • Chief Commercial Officer: Brad Wrigley

  • Head of Business Development: David Corr

  • Board Member: Frank Walsh

  • Operations Manager: Dr Ciara O’Donovan

  • Bioinformatician: Marcus O’Brien

  • Senior Bioinformatician: Dr Shriram Patel

  • Laboratory Technicians: Ramya Balasubramanian, Emmanuel Osei, Laura Finnegan, Vinicius Pedrosa

  • Scientific Advisors: Dr Fiona Crispie, Dr Orla O’Sullivan

  • Headquarters: Moorepark Food Research Centre, Teagasc, Fermoy, County Cork, P61 C996, Ireland

  • Number of Employees: 11-50 employees

  • Revenue: No information is available

  • Known For: Providing first-in-class technical and scientific microbiome services across various sectors including Nutrition, Pharmaceutical, Beauty, Healthcare, Sport, and Academia.


Products



Solutions Offered



Study Design


  • Description: Advice on cutting-edge design procedures with considerations for technical and biological replicates, appropriate sample sizes, sequencing depth, and potential confounders, among others.

  • Key Features:

  • State-of-the-art experimental design procedures

  • Control for fundamental problems in microbiome data

  • Foundation for analysis including time series and multi-omics data


Sample Processing


  • Description: Customized methodologies considering varying sampling methods, storage, DNA/RNA extraction, and sequencing protocols.

  • Key Features:

  • Proprietary methodologies for best outcomes

  • Detailed advice on sampling variables


Sequencing


  • Description: Experience with multiple major platforms, offering 16S rRNA or custom amplicons, shallow and deep shotgun sequencing of metagenomes and metatranscriptomes.

  • Key Features:

  • Positive and negative controls

  • Method of sequencing tailored to answer specific research questions


Compositional and Functional Microbiome Analysis


  • Description: Extensive profiling of microbiome composition and function, leveraging phylogenetic markers, and shotgun meta-genomic/transcriptomic sequencing.

  • Key Features:

  • Custom pipelines for species-level classification

  • Compositionally appropriate data analysis and statistical comparison


Biostatistical and Bioinformatic Analysis


  • Description: Comprehensive microbiome services with adaptable workflows, from quality control to advanced analysis.

  • Key Features:

  • Cloud-based scalable bioinformatics pipelines

  • State-of-the-art methodologies including contamination checking and advanced statistical modeling


Publication/Patent Ready Outputs


  • Description: Tailored outputs focused on clear communication of results, suitable for publication in peer-reviewed journals.

  • Key Features:

  • High-impact research presentation

  • Interactive project engagement


Recent Developments



  • SeqBiome expert microbiome analysis partner on the first placebo-controlled trial of vaginal microbiota transplantation (VMT) (July 4, 2024): Partnered with Atlantia Clinical Trials and Freya Biosciences to develop interventions for women's health concerning vaginal microbiota.


  • SeqBiome at Probiota Milan 2024 (February 8, 2024): Participation in the leading microbiome industry event hosted by NutraIngredients, represented by Head of Business Development David Corr.


  • Joint publication with Roche on microbiome links with diabetes and cancer immunotherapy (January 15, 2024): Co-authored a publication in Immuno Horizons exploring significant links between microbiome, diabetes, and cancer immunotherapy.


  • Benefits of fermented foods reviewed in Nature journal (January 15, 2024): CTO Prof Paul Cotter was senior author on a publication in Nature Reviews Gastroenterology discussing benefits of fermented foods.


  • Sponsorship of Boston conference (November 10, 2023): CEO Marcus Claesson presented research on the gut microbiome at a Boston conference.


  • Microbiome and performance discussion with Real Madrid (September 6, 2023): CTO Paul Cotter discussed the gut microbiome's role in athlete performance at an event with Abbott-Nutrition and Real Madrid CF.


SeqBiome has shown a strong recent track record of leadership in microbiome analysis and research, evident from their participation in significant studies and respected industry events.